Summary
57 / 100 · Bulios Score
What speaks for it
- Revenue grew by 17% a year over the last 3 years.
- It earns 17 BRL a year on every 100 BRL of invested capital.
- Analysts expect revenue to grow by 11% this fiscal year.
What to watch
- It cut its dividend by 16% last year.
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 11% a year over the last 3 years.
- Out of every 100 BRL of revenue, only 2.1 BRL is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.7 BRL for 1 BRL of yearly profit. Over the last five years it was 1,503.3 BRL on average.
Valuation in detailIs it growing?
SlowlyRevenue (BRL)
Diluted EPS (BRL)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 17% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share fell by 11% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 BRL of revenue goes
- Cost of sales 68 BRL
- Sales and administration 26 BRL
- Taxes and other 3.9 BRL
- Net profit 2.1 BRL
Net profit, industry median (Medical - Pharmaceuticals) 4.8 BRL
Out of every 100 BRL of revenue, 2.1 BRL is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 33.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, stretched- Yield
- 4.81%
- Paid out of profit
- 56%
You receive R$ 0.26 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail